Eyal C. Attar
2020
In 2020, Eyal C. Attar earned a total compensation of $2M as Chief Medical Officer at Aprea Therapeutics, a 66% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $192,610 |
|---|---|
| Option Awards | $1,345,850 |
| Salary | $437,750 |
| Total | $1,976,210 |
Attar received $1.3M in option awards, accounting for 68% of the total pay in 2020.
Attar also received $192.6K in non-equity incentive plan and $437.8K in salary.
Rankings
In 2020, Eyal C. Attar's compensation ranked 5,567th out of 13,090 executives tracked by ExecPay. In other words, Attar earned more than 57.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,567 out of 13,090 | 58th |
Division Manufacturing | 2,296 out of 5,621 | 59th |
Major group Chemicals And Allied Products | 919 out of 2,254 | 59th |
Industry group Drugs | 795 out of 1,954 | 59th |
Industry Pharmaceutical Preparations | 591 out of 1,459 | 60th |
Source: SEC filing on April 28, 2021.
Attar's colleagues
We found two more compensation records of executives who worked with Eyal C. Attar at Aprea Therapeutics in 2020.
News
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020